ADRB3 and Other metabolic disease: Attempts to stimulate BAT and beiging of WAT in humans using β3-AR agonists have met with only limited success, perhaps due to β3-AR downregulation in response to chronic ligand exposure and/or metabolic disease–induced inflammation, processes referred to as homologous and heterologous receptor desensitization, respectively (27).